By PPN News Staff
The FDA approved lefamulin (Xenleta, Nabriva Therapeutics) to treat adults with community-acquired bacterial pneumonia (CABP).
The safety and efficacy of lefamulin, taken orally or intravenously, were evaluated in two clinical trials—LEAP 1 and LEAP 2—involving a total of 1,289 patients with CABP. In the pooled trials, the median age of patients treated with lefamulin was 61 years (range, 19-97 years); 42% of patients were aged 65 years or older, and 18% were 75